Constitutive activation of NF-κB has been reported in almost 40% of AML cases [34] and studies indicate that aberrant activation of NF-κB is a crucial event responsible for resistance to cytarabine [35]. This evidence concerns the gene NFKB1 and acute myeloid leukemia.